---
figid: PMC3125986__nihms300587f3
figlink: /pmc/articles/PMC3125986/figure/F3/
number: Fig. 3
caption: The KATP channel determines, in part, the membrane potential of the smooth
  muscle cell and, hence, the contractile state. Vasoactive factors that inhibit KATP
  activity cause membrane depolarization, activation of voltage-dependent Ca2+-channels
  (VDCC), a rise in intracellular [Ca2+] and smooth muscle contraction. Conversely,
  factors that activate KATP prevent the depolarization-dependent rise in [Ca2+] and
  promote smooth muscle dilation. (A) Endogenous vasodilators, including epinephrine,
  adenosine, prostacyclin (PGl2), calcitonin-generated peptide (CGRP), and the vasoactive
  intestinal peptide (VIP), stimulate KATP activity through the classic G-protein
  (Gs)/adenylate cyclase (AC)/protein kinase A (PKA) signaling pathway. Serine/threonine
  phosphorylation at several key residue in SUR2B (Thr633, Ser1387, and Ser1465) is
  thought to underlie channel activation. Conversely, nitric oxide activates KATP
  through the protein kinase G (PKG) signaling pathway. Hypoxia and metabolic poisons
  (dinitrophenol and deoxygluxose) indirectly activate KATP by suppressing oxidative
  phosphorylation, resulting in a decrease in the ATP/ADP levels. The K+-channel opener
  drugs (KCOs) (eg. pinacidil and diazoxide) promote their anti-hypertensive effects
  by opening vascular smooth KATP channels via interaction with the SUR2B subunit.
  (B) Vasoconstrictor agonists that target VSM KATP to promote contraction include
  the neurotransmitter serotonin (5-HT), angiotensin-II, endothelin-I, and the pro-inflammatory
  histamine. Binding of vasoconstrictors to the G-protein receptor subtypes, Gi or
  Gq, indirectly activates the PKC-ε isoform. In turn, PKCε-mediated phosphorylation
  of a serine-rich motif in the C-terminus of Kir6.1 results in a decrease in the
  frequency of channel openings. Ca2+-activated calcineurin (phosphatase type 2B)
  inhibits VSM KATP although the mechanism is unclear. Sulfonylurea compounds (e.g
  glibenclamide) induce vasoconstriction by binding to the SUR2B subunit causing KATP
  channel closure.
pmcid: PMC3125986
papertitle: 'Muscle KATP Channels: Recent Insights to Energy Sensing and Myoprotection.'
reftext: Thomas P. Flagg, et al. Physiol Rev. ;90(3):799-829.
pmc_ranked_result_index: '117003'
pathway_score: 0.9293783
filename: nihms300587f3.jpg
figtitle: 'Muscle KATP Channels: Recent Insights to Energy Sensing and Myoprotection'
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3125986__nihms300587f3.html
  '@type': Dataset
  description: The KATP channel determines, in part, the membrane potential of the
    smooth muscle cell and, hence, the contractile state. Vasoactive factors that
    inhibit KATP activity cause membrane depolarization, activation of voltage-dependent
    Ca2+-channels (VDCC), a rise in intracellular [Ca2+] and smooth muscle contraction.
    Conversely, factors that activate KATP prevent the depolarization-dependent rise
    in [Ca2+] and promote smooth muscle dilation. (A) Endogenous vasodilators, including
    epinephrine, adenosine, prostacyclin (PGl2), calcitonin-generated peptide (CGRP),
    and the vasoactive intestinal peptide (VIP), stimulate KATP activity through the
    classic G-protein (Gs)/adenylate cyclase (AC)/protein kinase A (PKA) signaling
    pathway. Serine/threonine phosphorylation at several key residue in SUR2B (Thr633,
    Ser1387, and Ser1465) is thought to underlie channel activation. Conversely, nitric
    oxide activates KATP through the protein kinase G (PKG) signaling pathway. Hypoxia
    and metabolic poisons (dinitrophenol and deoxygluxose) indirectly activate KATP
    by suppressing oxidative phosphorylation, resulting in a decrease in the ATP/ADP
    levels. The K+-channel opener drugs (KCOs) (eg. pinacidil and diazoxide) promote
    their anti-hypertensive effects by opening vascular smooth KATP channels via interaction
    with the SUR2B subunit. (B) Vasoconstrictor agonists that target VSM KATP to promote
    contraction include the neurotransmitter serotonin (5-HT), angiotensin-II, endothelin-I,
    and the pro-inflammatory histamine. Binding of vasoconstrictors to the G-protein
    receptor subtypes, Gi or Gq, indirectly activates the PKC-ε isoform. In turn,
    PKCε-mediated phosphorylation of a serine-rich motif in the C-terminus of Kir6.1
    results in a decrease in the frequency of channel openings. Ca2+-activated calcineurin
    (phosphatase type 2B) inhibits VSM KATP although the mechanism is unclear. Sulfonylurea
    compounds (e.g glibenclamide) induce vasoconstriction by binding to the SUR2B
    subunit causing KATP channel closure.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ADCY10
  - PLCZ1
  - PRKG1
  - ADCY1
  - ADCY2
  - PLCD4
  - ADCY3
  - ADCY5
  - ADCY6
  - PRKAR2B
  - PPP3CA
  - PRKAR1A
  - PRKAR2A
  - PLCB1
  - PLCB3
  - PLCB2
  - PLCD3
  - PLCG2
  - PLCG1
  - VIP
  - PPP3CB
  - PRKAR1B
  - S100A12
  - PLCE1
  - ADCY7
  - PPP3R2
  - PLCD1
  - ADCY4
  - PPP3R1
  - PLCB4
  - PRKACG
  - PPP3CC
  - PRKACB
  - GNAL
  - ADCY8
  - ADCY9
  - SDHD
  - PRKACA
  - GNAS
  - adenosine
  - deoxyglucose
  - dinitrophenol
  - epinephrine
  - histamine
  - nitric oxide
  - norepinephrine
  - serotonin
genes:
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY10
  entrez: '55811'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCZ1
  entrez: '89869'
- word: PKG
  symbol: PKG
  source: hgnc_alias_symbol
  hgnc_symbol: PRKG1
  entrez: '5592'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY1
  entrez: '107'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY2
  entrez: '108'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD4
  entrez: '84812'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY3
  entrez: '109'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY5
  entrez: '111'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY6
  entrez: '112'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: calcineurin
  symbol: CALCINEURIN
  source: bioentities_symbol
  hgnc_symbol: PPP3CA
  entrez: '5530'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB1
  entrez: '23236'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB3
  entrez: '5331'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB2
  entrez: '5330'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD3
  entrez: '113026'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: VIP
  symbol: VIP
  source: hgnc_symbol
  hgnc_symbol: VIP
  entrez: '7432'
- word: calcineurin
  symbol: CALCINEURIN
  source: bioentities_symbol
  hgnc_symbol: PPP3CB
  entrez: '5532'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: CGRP
  symbol: CGRP
  source: hgnc_alias_symbol
  hgnc_symbol: S100A12
  entrez: '6283'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCE1
  entrez: '51196'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY7
  entrez: '113'
- word: calcineurin
  symbol: CALCINEURIN
  source: bioentities_symbol
  hgnc_symbol: PPP3R2
  entrez: '5535'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD1
  entrez: '5333'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY4
  entrez: '196883'
- word: calcineurin
  symbol: CALCINEURIN
  source: bioentities_symbol
  hgnc_symbol: PPP3R1
  entrez: '5534'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB4
  entrez: '5332'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: calcineurin
  symbol: CALCINEURIN
  source: bioentities_symbol
  hgnc_symbol: PPP3CC
  entrez: '5533'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: Gs
  symbol: Gs
  source: bioentities_symbol
  hgnc_symbol: GNAL
  entrez: '2774'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY8
  entrez: '114'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY9
  entrez: '115'
- word: PGL,
  symbol: PGL
  source: hgnc_prev_symbol
  hgnc_symbol: SDHD
  entrez: '6392'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: Gs
  symbol: Gs
  source: bioentities_symbol
  hgnc_symbol: GNAS
  entrez: '2778'
chemicals:
- word: adenosine
  source: MESH
  identifier: D000241
- word: deoxyglucose
  source: MESH
  identifier: D003847
- word: dinitrophenol
  source: MESH
  identifier: D004140
- word: epinephrine
  source: MESH
  identifier: D004837
- word: histamine
  source: MESH
  identifier: D006632
- word: nitric oxide
  source: MESH
  identifier: D009569
- word: norepinephrine
  source: MESH
  identifier: D009638
- word: serotonin
  source: MESH
  identifier: D012701
diseases: []
---
